

Traws Pharma shares fell after UK regulators deferred a planned influenza challenge study for tivoxavir marboxil, delaying clinical development.
You can purchase shares of Traws Pharma (NASDAQ:TRAW) through any online brokerage.
Other companies in Traws Pharma’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Traws Pharma has a consensus price target of $1.00.
The stock price for Traws Pharma (NASDAQ: TRAW) is $0.22 last updated November 5, 2026 at 3:54 PM EST.
There are no upcoming dividends for Traws Pharma.
Traws Pharma does not have any upcoming earnings scheduled.
There is no upcoming split for Traws Pharma.
Traws Pharma is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent...